Skip to Content

Generic Omnaris Availability

Omnaris is a brand name of ciclesonide nasal, approved by the FDA in the following formulation(s):

OMNARIS (ciclesonide - spray, metered;nasal)

  • Manufacturer: ASTRAZENECA PHARMS
    Approval date: October 20, 2006
    Strength(s): 0.05MG/INH [RLD]

Has a generic version of Omnaris been approved?

No. There is currently no therapeutically equivalent version of Omnaris available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Omnaris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Ciclesonide contained pharmaceutical composition for application to mucosa
    Patent 6,767,901
    Issued: July 27, 2004
    Inventor(s): Atsuhiro; Nagano & Yoshihisa; Nishibe & Kazuya; Takanashi
    Assignee(s): Altana Pharma AG

    The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.

    Patent expiration dates:

    • October 21, 2020
      ✓ 
      Drug product
  • Pharmaceutical composition for application to mucosa
    Patent 6,939,559
    Issued: September 6, 2005
    Inventor(s): Nishibe; Yoshihisa & Kinoshita; Wataru & Kawabe; Hiroyuki
    Assignee(s): Teijin Limited

    The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.

    Patent expiration dates:

    • April 21, 2019
      ✓ 
      Drug product
  • Pharmaceutical composition for application to mucosa
    Patent 7,235,247
    Issued: June 26, 2007
    Inventor(s): Nishibe; Yoshihisa & Kinoshita; Wataru & Kawabe; Hiroyuki
    Assignee(s): Teijin Pharma Limited

    The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high permeability to the blood at the mucosa. The present invention further provides a pharmaceutical composition for application to the mucosa comprising a hemostatic agent and a medicament. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to permeability and retentivity at the mucosa.

    Patent expiration dates:

    • April 21, 2019
      ✓ 
      Drug product
  • Use of ciclesonide for the treatment of respiratory diseases
    Patent 8,371,292
    Issued: February 12, 2013
    Assignee(s): Nycomed GmbH

    The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.

    Patent expiration dates:

    • February 1, 2028
      ✓ 
      Patent use: TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
  • Ciclesonide containing aqueous pharmaceutical composition
    Patent 8,383,611
    Issued: February 26, 2013
    Assignee(s): Nycomed GmbH

    The present invention provides an aqueous pharmaceutical composition containing ciclesonide and hydroxypropyl-methylcellulose, wherein the ciclesonide is dispersed in an aqueous medium in the form of solid particles. The composition is able to avoid variations in the concentrations of ciclesonide during production as well as avoid decreases in the recovery rate of ciclesonide.

    Patent expiration dates:

    • October 20, 2020
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide